

Datasheet: MCA1781R

BATCH NUMBER 159901

Description:	MOUSE ANTI CANINE CD21
Specificity:	CD21
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	CA2.1D6
Isotype:	IgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			1/100
Immunohistology - Frozen (1)	▪			
Immunohistology - Paraffin		▪		
ELISA			▪	
Immunoprecipitation	▪			
Western Blotting			▪	

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

(1)The epitope recognised by this antibody is reported to be sensitive to formaldehyde fixation and tissue processing. Bio-Rad recommends the use of acetone fixation for frozen sections.

Target Species

Dog

Species Cross Reactivity

Reacts with: Horse, Cat, Raccoon

N.B. Antibody reactivity and working conditions may vary between species. Cross reactivity is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information.

Product Form	Purified IgG - liquid
Preparation	Purified IgG prepared by affinity chromatography on Protein A
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.09% Sodium Azide
Approx. Protein Concentrations	IgG concentration 1.0 mg/ml
RRID	AB_323665
Specificity	<p>Mouse anti Canine CD21 antibody, clone CA2.1D6 recognizes canine CD21, also known as Complement receptor type 2. CD21 is a cell surface antigen expressed by canine B lymphocytes.</p> <p>The antigen recognized may be the canine homologue of human CD21, but this has not been fully confirmed.</p> <p>Mouse anti Canine CD21 antibody , clone CA2.1D6 also recognizes the CD21 antigen in Felids. Expression in cats is analogous to that seen in dogs with strong expression on lymphocytes, in a manner mutually exclusive with expression of CD4 or CD8. Mouse anti Canine CD21 antibody, clone CA2.1D6 immunoprecipitates a ~145 kDa protein from feline lymphocytes, similar to the protein immunoprecipitated by the antibody from canine lymphocytes (Dean et al. 1996).</p>
Flow Cytometry	Use 10ul of the suggested working dilution to label 10 ⁶ cells or 100ul whole blood.
References	<ol style="list-style-type: none"> Cobbold, S. & Metcalfe, S. (1994) Monoclonal antibodies that define canine homologues of human CD antigens: summary of the First International Canine Leukocyte Antigen Workshop (CLAW). Tissue Antigens. 43 (3): 137-54. Brodersen, R. et al. (1998) Analysis of the immunological cross reactivities of 213 well characterized monoclonal antibodies with specificities against various leucocyte surface antigens of human and 11 animal species. Vet Immunol Immunopathol. 64 (1): 1-13. Dean, G.A. et al. (1996) Proviral burden and infection kinetics of feline immunodeficiency virus in lymphocyte subsets of blood and lymph node. J Virol. 70 (8): 5165-9. Faldyna, M. et al. (2004) Lymphocyte subsets in synovial fluid from clinically healthy joints of dogs. Acta Vet. Brno 73: 73-8. Bund, D. et al. (2010) Canine-DCs using different serum-free methods as an approach to provide an animal-model for immunotherapeutic strategies. Cell Immunol. 263: 88-98. Huang, Y.C. et al. (2008) CD5-low expression lymphocytes in canine peripheral blood show characteristics of natural killer cells. J Leukoc Biol. 84: 1501-10. Mortarino, M. et al. (2009) ZAP-70 and Syk expression in canine lymphoid cells and preliminary results on leukaemia cases. Vet Immunol Immunopathol. 128: 395-401. Reggeti, F. et al. (2008) CD134 and CXCR4 expression corresponds to feline

- immunodeficiency virus infection of lymphocytes, macrophages and dendritic cells. [J Gen Virol. 89: 277-87.](#)
9. Wang, Y.S. *et al.* (2007) Characterization of canine monocyte-derived dendritic cells with phenotypic and functional differentiation. [Can J Vet Res. 71: 165-74.](#)
 10. Lankford, S. *et al.* (2008) Cloning of feline FOXP3 and detection of expression in CD4+CD25+ regulatory T cells. [Vet Immunol Immunopathol. 122: 159-66.](#)
 11. Araujo, M.S. *et al.* (2011) Immunological changes in canine peripheral blood leukocytes triggered by immunization with first or second generation vaccines against canine visceral leishmaniasis. [Vet Immunol Immunopathol. 141: 64-75.](#)
 12. Estrela-Lima, A. *et al.* (2010) Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates. [BMC Cancer. 10: 256.](#)
 13. Horn, P.A. *et al.* (2004) Efficient lentiviral gene transfer to canine repopulating cells using an overnight transduction protocol. [Blood. 103: 3710-6.](#)
 14. Hsiao, Y.W. *et al.* (2004) Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-beta 1 and restores the lymphokine-activated killing activity. [J Immunol. 172: 1508-14.](#)
 15. Jubala, C.M. *et al.* (2005) CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma. [Vet Pathol. 42: 468-76.](#)
 16. Gaurnier-Hausser, A. *et al.* (2011) NEMO-Binding Domain Peptide Inhibits Constitutive NF- κ B Activity and Reduces Tumor Burden in a Canine Model of Relapsed, Refractory Diffuse Large B-Cell Lymphoma. [Clin Cancer Res. 17: 4661-71.](#)
 17. Maiolini, A. *et al.* (2012) Toll-like receptors 4 and 9 are responsible for the maintenance of the inflammatory reaction in canine steroid-responsive meningitis-arteritis, a large animal model for neutrophilic meningitis. [J Neuroinflammation. 9: 226.](#)
 18. Cave, N.J. *et al.* (2012) Systemic effects of periodontal disease in cats. [Vet Q. 32: 131-44.](#)
 19. Yuasa, K. *et al.* (2007) Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products. [Gene Ther. 14: 1249-60.](#)
 20. Aresu, L. *et al.* (2014) VEGF and MMP-9: biomarkers for canine lymphoma. [Vet Comp Oncol. 12: 29-36.](#)
 21. Heinrich, F. *et al.* (2015) Immunophenotyping of immune cell populations in the raccoon (*Procyon lotor*). [Vet Immunol Immunopathol. 168 \(3-4\): 140-6.](#)
 22. Gelain, M.E. *et al.* (2014) CD44 in canine leukemia: analysis of mRNA and protein expression in peripheral blood. [Vet Immunol Immunopathol. 159 \(1-2\): 91-6.](#)
 23. Michael, H.T. *et al.* (2013) Isolation and characterization of canine natural killer cells. [Vet Immunol Immunopathol. 155 \(3\): 211-7.](#)
 24. Mitchell, L. *et al.* (2012) Induction of remission results in spontaneous enhancement of anti-tumor cytotoxic T-lymphocyte activity in dogs with B cell lymphoma. [Vet Immunol Immunopathol. 145 \(3-4\): 597-603.](#)
 25. Bonnefont-Rebeix, C. *et al.* (2016) Characterization of a novel canine T-cell line established from a spontaneously occurring aggressive T-cell lymphoma with large granular cell morphology. [Immunobiology. 221 \(1\): 12-22.](#)
 26. Izci C *et al.* (2015) Clinical and light microscopic studies of the conjunctival tissues of dogs with bilateral keratoconjunctivitis sicca before and after treatment with topical 2% cyclosporine. [Biotech Histochem. 90 \(3\): 223-30.](#)

27. Ledbetter, E.C. *et al.* (2016) Clinical and immunological assessment of therapeutic immunization with a subunit vaccine for recurrent ocular canine herpesvirus-1 infection in dogs. [Vet Microbiol. 197: 102-10.](#)
28. Lin, S-C. *et al.* (2014) Immune Characterization of Peripheral Blood Mononuclear cells of the Dogs Restored from Innoculation of Canine Transmissible Venereal Tumor Cells. [Tai Vet J. 40 \(04\): 181-90.](#)
29. Herry, V. *et al.* (2017) Local immunization impacts the response of dairy cows to *Escherichia coli* mastitis. [Sci Rep. 7 \(1\): 3441.](#)
30. Gibbons, N. *et al.* (2017) Phenotypic heterogeneity of peripheral monocytes in healthy dogs. [Vet Immunol Immunopathol. 190: 26-30.](#)
31. Martini, V. *et al.* (2018) Flow cytometry for feline lymphoma: a retrospective study regarding pre-analytical factors possibly affecting the quality of samples. [J Feline Med Surg. 20 \(6\): 494-501.](#)
32. Declue, A.E. *et al.* (2018) Identification of immunologic and clinical characteristics that predict inflammatory response to C. Novyi-NT bacteriolytic immunotherapy. [BMC Vet Res. 14 \(1\): 119.](#)
33. DaSilva, A.V.A. *et al.* (2018) Morphophysiological changes in the splenic extracellular matrix of *Leishmania infantum*-naturally infected dogs is associated with alterations in lymphoid niches and the CD4+ T cell frequency in spleens. [PLoS Negl Trop Dis. 12 \(4\): e0006445.](#)
34. Schmidli, M.R. *et al.* (2018) Inflammatory pattern of the infrapatellar fat pad in dogs with canine cruciate ligament disease. [BMC Vet Res. 14 \(1\): 161.](#)
35. Miranda, L.H.M de M. *et al.* (2018) Co-infection with feline retrovirus is related to changes in immunological parameters of cats with sporotrichosis. [PLoS One. 13 \(11\): e0207644.](#)
36. Maeta, N. *et al.* (2019) Lymphokine-activated killer cell transplantation after anti-cancer treatment in two aged cats. [Open Vet J. 9 \(2\): 147-50.](#)
37. Sato, M. *et al.* (2018) Prognostic significance of hypermethylation of death-associated protein kinase (DAPK) gene CpG island in dogs with high-grade B-cell lymphoma. [Vet Comp Oncol. 16 \(3\): 409-15.](#)
38. Aricò, A. *et al.* (2013) The role of vascular endothelial growth factor and matrix metalloproteinases in canine lymphoma: *in vivo* and *in vitro* study. [BMC Vet Res. 9: 94.](#)
39. Aguiar-Soares, R.D.O. *et al.* (2020) Phase I and II Clinical Trial Comparing the LBSap, Leishmune[®], and Leish-Tec[®] Vaccines against Canine Visceral Leishmaniasis. [Vaccines \(Basel\). 8 \(4\)Nov 17 \[Epub ahead of print\].](#)
40. Jimbo, S. *et al.* (2019) Natural and inducible regulatory B cells are widely distributed in ovine lymphoid tissues. [Vet Immunol Immunopathol. 211: 44-8.](#)
41. Martini, V. *et al.* (2019) Prognostic role of non-neoplastic lymphocytes in lymph node aspirates from dogs with diffuse large B-cell lymphoma treated with chemo-immunotherapy. [Res Vet Sci. 125: 130-5.](#)
42. Wolf-Ringwall, A. *et al.* (2020) Prospective evaluation of flow cytometric characteristics, histopathologic diagnosis and clinical outcome in dogs with naïve B-cell lymphoma treated with a 19-week CHOP protocol. [Vet Comp Oncol. 18 \(3\): 342-52.](#)
43. Lucassen, A. *et al.* (2021) A *Saccharomyces cerevisiae* Fermentation Product (Olimond BB) Alters the Early Response after Influenza Vaccination in Racehorses. [Animals \(Basel\). 11\(9\):2726.](#)
44. Lee, J. *et al.* (2021) Canine Natural Killer Cell-Derived Exosomes Exhibit Antitumor

- Activity in a Mouse Model of Canine Mammary Tumor. [Biomed Res Int. 2021: 6690704.](#)
45. Shin, N. *et al.* (2018) INCB040093 Is a Novel PI3K δ Inhibitor for the Treatment of B Cell Lymphoid Malignancies. [J Pharmacol Exp Ther. 364 \(1\): 120-30.](#)
46. Grudzien, M. *et al.* (2021) A newly established canine NK-type cell line and its cytotoxic properties. [Vet Comp Oncol. 19 \(3\): 567-77.](#)
47. Yang, Y. *et al.* (2021) Canine Multicentric Large B Cell Lymphoma with Increased Mott Cells Diagnosed by Flow Cytometry [Journal of Veterinary Clinics. 38 \(1\): 36-40.](#)
48. Lee, S.H. *et al.* (2021) Safety and immunological effects of recombinant canine IL-15 in dogs. [Cytokine. 148: 155599.](#)
49. Knebel, A. *et al.* (2021) Measurement of canine Th17 cells by flow cytometry. [Vet Immunol Immunopathol. 243: 110366.](#)
50. Riccardo, F. *et al.* (2022) Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial. [J Immunother Cancer. 10\(5\):e004007. \[Epub ahead of print\].](#)
51. Jaensch, S. *et al.* (2022) Clinicopathologic and immunophenotypic features in dogs with presumptive large granular lymphocyte leukaemia [Australian Veterinary Journal. \[Epub ahead of print\].](#)
52. Troupel, T. *et al.* (2022) Generalised idiopathic polymyositis mimicking masticatory myositis in a dog [Vet Rec Case Rep. e452 \[Epub ahead of print\].](#)

Storage This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.

Guarantee 12 months from date of despatch

Health And Safety Information Material Safety Datasheet documentation #10040 available at: 10040: <https://www.bio-rad-antibodies.com/uploads/MSDS/10040.pdf>

Regulatory For research purposes only

Related Products

Recommended Secondary Antibodies

- | | |
|---|---|
| Goat Anti Mouse IgG (STAR77...) | HRP |
| Rabbit Anti Mouse IgG (STAR12...) | RPE |
| Goat Anti Mouse IgG (STAR70...) | FITC |
| Goat Anti Mouse IgG IgA IgM (STAR87...) | Alk. Phos. , HRP |
| Goat Anti Mouse IgG (STAR76...) | RPE |
| Goat Anti Mouse IgG (H/L) (STAR117...) | Alk. Phos. , DyLight@488 , DyLight@550 , DyLight@650 , DyLight@680 , DyLight@800 , FITC , HRP |
| Rabbit Anti Mouse IgG (STAR13...) | HRP |
| Goat Anti Mouse IgG (Fc) (STAR120...) | FITC , HRP |

Rabbit Anti Mouse IgG (STAR9...) [FITC](#)

Recommended Negative Controls

MOUSE IgG1 NEGATIVE CONTROL (MCA928)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets

'M383591:210513'

Printed on 08 Feb 2023

© 2023 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)